Search

CN-122005876-A - Medical ultrasonic hydrogel and preparation method thereof

CN122005876ACN 122005876 ACN122005876 ACN 122005876ACN-122005876-A

Abstract

The application belongs to the technical field of medical ultrasonic imaging agents, and particularly relates to medical ultrasonic hydrogel and a preparation method thereof. According to the application, through carrying out alkylation modification on tannic acid, the fat solubility of tannic acid is enhanced, the membrane of gram-positive bacteria and gram-negative bacteria is facilitated to permeate in a short period of time, the sterilization effect is exerted, and the sterilization rate of staphylococcus aureus and escherichia coli in 15 minutes can be higher than 95%. Meanwhile, the alkylated modified tannic acid is beneficial to reducing the sound attenuation of the hydrogel and the adhesion strength to the surface of skin tissues, so that the hydrogel can be conveniently peeled off from the surface of the skin and the ultrasonic probe can slide smoothly, and poor user experience caused by pulling the skin is avoided.

Inventors

  • WU QIANZI
  • AI GUO

Assignees

  • 华中科技大学同济医学院附属同济医院

Dates

Publication Date
20260512
Application Date
20260413

Claims (10)

  1. 1. The medical ultrasonic hydrogel comprises alkyl modified tannic acid, acrylamide, N-methylene bisacrylamide, an initiator and an accelerator; wherein the initiator is selected from one or two of ammonium persulfate and potassium persulfate; The accelerator is selected from tertiary amine compounds; the alkyl modified tannic acid is obtained by ring-opening reaction of an epoxy compound containing a C4-C16 alkyl side chain and phenolic hydroxyl of tannic acid.
  2. 2. The medical ultrasound hydrogel of claim 1, wherein the accelerator is selected from one or more of triethylamine, 2,4, 6-tris (dimethylaminomethyl) phenol, and N, N' -tetramethyl ethylenediamine; And/or the alkyl side chain of the epoxy compound containing a C4-C16 alkyl side chain is selected from a C4-C16 linear alkyl group, a branched alkyl group or a cycloalkyl group.
  3. 3. The medical ultrasonic hydrogel according to claim 1, wherein the epoxy compound containing a C4-C16 alkyl side chain is selected from any one of lauryl glycidyl ether, isooctyl glycidyl ether, and cyclohexane epoxy.
  4. 4. The ultrasonic medical hydrogel according to claim 1, wherein the alkyl-modified tannic acid is obtained by reacting tannic acid with an epoxy compound having a C4-C16 alkyl side chain under catalysis of a tetraalkyl halide at 80-120 ℃.
  5. 5. The medical ultrasound hydrogel according to claim 4, wherein the tetraalkyl halide is selected from any one of cetyltrimethylammonium chloride, cetyltrimethylammonium bromide, cetyltriethylammonium chloride, cetyltriethylammonium bromide, tetrabutylammonium chloride or tetrabutylammonium bromide.
  6. 6. The medical ultrasonic hydrogel according to claim 4, wherein the molar ratio of tannic acid to the epoxy compound having a C4-C16 alkyl side chain is 1 (5-10).
  7. 7. The medical ultrasonic hydrogel according to claim 4, wherein the tetraalkyl halide is used in an amount of 0.5 to 3wt% based on the total mass of tannic acid and the epoxy compound having a C4 to C16 alkyl side chain.
  8. 8. The medical ultrasonic hydrogel according to claim 1, wherein the raw materials comprise, by mass, 45-55 parts of acrylamide, 0.1-0.5 part of N, N-methylenebisacrylamide, 0.5-1 part of an initiator, 0.1-0.2 part of an accelerator, and 2-6 parts of alkyl modified tannic acid.
  9. 9. A method of preparing a medical ultrasound hydrogel according to any one of claims 1 to 8, comprising: S1, dissolving acrylamide in deionized water at room temperature to obtain an acrylamide aqueous solution; S2, adding N, N-methylene bisacrylamide, an initiator, an accelerator and alkyl modified tannic acid into an acrylamide aqueous solution at the temperature of 0 ℃ to room temperature, mixing and stirring to obtain a pregel solution; S3, transferring the pre-gel solution into a mold, and standing and polymerizing for 1-24 hours at 35-60 ℃ to obtain hydrogel; S4, freezing the hydrogel for 1-12 hours at the temperature below-20 ℃ and then freeze-drying for 1-24 hours to obtain the dried hydrogel.
  10. 10. Use of the medical ultrasound hydrogel of any one of claims 1-8 as an ultrasound imaging agent.

Description

Medical ultrasonic hydrogel and preparation method thereof Technical Field The application belongs to the technical field of medical ultrasonic imaging agents, and particularly relates to medical ultrasonic hydrogel and a preparation method thereof. Background Ultrasonic examination is one of the mainstream medical imaging means, which displays the internal tissue structure of the human body by using ultrasonic waves, and provides a basis for disease diagnosis. The B-type ultrasonic is the most common ultrasonic examination type, can display two-dimensional images of tissues in real time, and is widely applied to soft tissues, visceral organ examination and prenatal diagnosis. Based on B-mode ultrasound imaging, elastography techniques have further evolved. Ultrasonic elastography measures the elastic modulus of soft tissues by quantitative analysis, can generate an elastic distribution map of the measured tissues, and is now applied to examination of mammary glands, thyroid glands, livers and prostate glands. In clinical medicine, various diseases such as breast cancer and liver cirrhosis are accompanied by the sclerosis of corresponding organs or lesions. Whereas the traditional palpation method belongs to subjective qualitative analysis, and the diagnosis result depends on the clinical experience of doctors. Thus, ultrasound elastography is seen as a reliable, objective tool for achieving accurate diagnosis. To ensure diagnostic efficacy of ultrasound imaging, a coupling agent must be used clinically. The liquid couplant is capable of filling a void between the probe and the skin, facilitating conduction of ultrasonic energy from the probe to the skin. However, in the high local curvature parts such as skin tumor, finger, elbow and the like, the probe cannot be well attached to the skin surface when the liquid coupling agent is used due to the limitation of the geometric structure, so that air retention can be generated between the probe and the skin, and the ultrasonic imaging effect is poor. Accordingly, there is a need in the clinic for an acoustic impedance matching flexible material that can withstand pressure to ensure accuracy of elastography, has excellent compliance to conform to skin surfaces of high local curvature, and at the same time can alleviate stress concentrations in tissue. The hydrogel takes water as a dispersion medium, has physical and physiological characteristics similar to living tissues, has acoustic impedance similar to water, is an excellent sound transmission medium, has no cytotoxicity and has good biocompatibility. In addition, the hydrogel has elasticity and adjustable modulus, and compared with a liquid coupling agent, the hydrogel has no bubble retention and can relieve stress concentration. However, the hydrogel has the problems of no antibacterial effect, high adhesion strength, influence on user experience and high sound attenuation rate, and needs to be further improved, so that the hydrogel is used for high-resolution and high-precision ultrasonic detection in clinical diagnosis. Disclosure of Invention Aiming at the defects of the prior art, tannic acid is alkylated and modified and is used in the acrylamide composite hydrogel, so that the sound attenuation rate of the hydrogel and the adhesion strength on the surface of pigskin are reduced, and the killing effect of gram-positive bacteria and gram-negative bacteria in a short period is improved. In order to achieve the technical purpose, the application adopts the following technical scheme: In a first aspect, a medical ultrasonic hydrogel comprises alkyl modified tannic acid, acrylamide, N-methylene bisacrylamide, an initiator and an accelerator; wherein the initiator is selected from one or two of ammonium persulfate and potassium persulfate; The accelerator is selected from tertiary amine compounds; preferably, the promoter is selected from one or more of triethylamine, 2,4, 6-tris (dimethylaminomethyl) phenol and N, N' -tetramethyl ethylenediamine; still more preferably, the accelerator is selected from the group consisting of N, N' -tetramethyl ethylenediamine. The alkyl modified tannic acid is obtained by ring-opening reaction of an epoxy compound containing a C4-C16 alkyl side chain and phenolic hydroxyl of tannic acid; preferably, the alkyl side chain of the epoxy compound containing a C4-C16 alkyl side chain is selected from a C4-C16 linear alkyl, branched alkyl or cycloalkyl group; Preferably, the epoxy compound containing a C4-C16 alkyl side chain is selected from any one of lauryl alcohol glycidyl ether, isooctyl glycidyl ether or cyclohexane epoxy; Further, the alkyl modified tannic acid is obtained by reacting tannic acid with an epoxy compound containing a C4-C16 alkyl side chain under the catalysis of tetraalkyl halide at 80-120 ℃; preferably, the tetraalkyl halide is selected from any one of cetyltrimethylammonium chloride, cetyltrimethylammonium bromide, cetyltriethylammonium chloride, cetyltrie